References

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: The French TMA reference center experience

10.1371/journal.pone.0010208 · 2010 · External reference

Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature

10.1097/00005792-196603000-00003 · 1966 · External reference

Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features

10.1111/j.1365-2141.2008.07276.x · 2008 · External reference

ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura

10.1002/humu.21143 · 2010 · External reference

Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine

10.1002/rth2.12160 · 2019 · External reference

A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP

10.1182/blood.2020008021 · 2021 · External reference

Phase 2 randomized, placebo-controlled, double-blind, multicenter study of recombinant ADAMTS13 in patients with immune-mediated thrombotic thrombocytopenic purpura [abstract]

10.1097/01.hs9.0000968132.86513.06 · 2023 · External reference

Impact of new medications on the treatment of immune TTP

10.1182/blood.2024026390 · 2025 · External reference

ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission

10.3324/haematol.11739 · 2008 · External reference

Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse

10.1111/j.1365-2141.2008.07107.x · 2008 · External reference

Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura

10.1182/blood-2016-06-724161 · 2016 · External reference

Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase

10.1177/20406207221112217 · 2022 · External reference

Redefining outcomes in immune TTP: an International Working Group consensus report

10.1182/blood.2020009150 · 2021 · External reference

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura

10.1182/blood-2014-01-550244 · 2014 · External reference

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura

10.1182/blood-2018-04-840090 · 2018 · External reference

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

2020 · External reference

A novel von Willebrand factor multimer ratio as marker of disease activity in thrombotic thrombocytopenic purpura

10.1182/bloodadvances.2023010028 · 2023 · External reference

Low ADAMTS13 activity is associated with an increased risk of ischemic stroke

10.1182/blood-2015-05-643338 · 2015 · External reference

von Willebrand factor, ADAMTS13, and the risk of mortality: the Rotterdam study

10.1161/atvbaha.116.308225 · 2016 · External reference

Low ADAMTS-13 activity and the risk of coronary heart disease – a prospective cohort study: the Rotterdam study

10.1111/jth.13479 · 2016 · External reference

Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients

10.1016/j.atherosclerosis.2009.04.013 · 2009 · External reference

High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women

10.1182/blood-2011-09-380618 · 2012 · External reference

Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors

10.1182/blood.2019001056 · 2019 · External reference

von Willebrand factor/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome

10.1182/bloodadvances.2019000979 · 2020 · External reference

Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura

10.1182/blood-2016-12-758656 · 2017 · External reference

FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay

10.1111/j.1365-2141.2005.05420.x · 2005 · External reference

Fast deisotoping algorithm and its implementation in the MSFragger search engine

10.1021/acs.jproteome.0c00544 · 2021 · External reference

MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics

10.1038/nmeth.4256 · 2017 · External reference

Fast quantitative analysis of timsTOF PASEF data with MSFragger and IonQuant

10.1074/mcp.tir120.002048 · 2020 · External reference

DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput

10.1038/s41592-019-0638-x · 2020 · External reference

Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ

10.1074/mcp.m113.031591 · 2014 · External reference

10.4236/oalib.1107821

10.4236/oalib.1107821 · External reference

Welcome to the Tidyverse

10.21105/joss.01686 · 2019 · External reference

limma powers differential expression analyses for RNA-sequencing and microarray studies

10.1093/nar/gkv007 · 2015 · External reference

Metascape provides a biologist-oriented resource for the analysis of systems-level datasets

10.1038/s41467-019-09234-6 · 2019 · External reference

Cytoscape: a software environment for integrated models of biomolecular interaction networks

10.1101/gr.1239303 · 2003 · External reference

Largest comparison between onset and relapses of acquired thrombotic thrombocytopenic purpura reveals severe neurological involvement and worse analytic parameters at debut

10.1007/s00277-024-05634-x · 2024 · External reference

Quantitative analysis of human red blood cell proteome

10.1021/acs.jproteome.7b00025 · 2017 · External reference

Oxidant stress and haemolysis of the human erythrocyte

10.2165/00139709-200423030-00004 · 2004 · External reference

Methemoglobinemia: etiology, pharmacology, and clinical management

10.1016/s0196-0644(99)70167-8 · 1999 · External reference

Plasma free hemoglobin is associated with LDH, AST, total bilirubin, and the hemolytic component in patients with sickle cell anemia

10.1182/blood-2022-158713 · 2022 · External reference

Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: The French TMA reference center experience

10.3324/haematol.2011.049676 · 2012 · External reference

Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience

10.1111/j.1537-2995.2007.01071.x · 2007 · External reference

The interaction of fibulin-1 with fibrinogen: a potential role in hemostasis and thrombosis

10.1074/jbc.270.33.19458 · 1995 · External reference

Behind the scenes of vitamin D binding protein: more than vitamin D binding

10.1016/j.beem.2015.06.006 · 2015 · External reference

Liver-derived Indian hedgehog (Ihh) couples fast-feed transition to thermogenic and metabolic homeostasis

10.1016/j.molmet.2026.102339 · 2026 · External reference

Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP

10.1182/bloodadvances.2021004971 · 2021 · External reference

Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13

10.1111/jth.13149 · 2015 · External reference

An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura

10.1111/jth.13922 · 2018 · External reference

Antibodies that conformationally activate ADAMTS13 allosterically enhance metalloprotease domain function

10.1182/bloodadvances.2019001375 · 2020 · External reference

Mechanistic insight into multiple antibody binding to ADAMTS13 in immune thrombotic thrombocytopenic purpura

10.1016/j.rpth.2024.102603 · 2024 · External reference

Unraveling antibody-induced structural dynamics in the ADAMTS13 CUB1-2 domains via HDX-MS

10.1182/bloodadvances.2024014950 · 2025 · External reference

A microfluidic approach reveals ongoing disease activity in thrombotic thrombocytopenic purpura patients despite clinical remission

10.1016/j.jtha.2025.06.027 · 2025 · External reference

Characterization and treatment of congenital thrombotic thrombocytopenic purpura

10.1182/blood-2018-11-884700 · 2019 · External reference

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

10.1182/blood.2020009801 · 2021 · External reference

Technical evaluation of plasma proteomics technologies

10.1021/acs.jproteome.5c00221 · 2025 · External reference